SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

DELSTRIGO

MRK·Merck & Co., Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 2018 (FDA) and 2018 (EMA).
Why 3/10
No hard, dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for Delstrigo in the next ~12 months. The drug is already approved and marketed. The recent FDA sNDA approval (October 1, 2026) and European Commission authorization update are already completed events. ImpactScore is 3 because Delstrigo is a small product within Merck's massive diversified portfolio.
Actionable Insight NEUTRAL

Delstrigo is a mature, marketed product with no upcoming binary catalyst. The recent FDA sNDA approval (October 1, 2026) and European Commission authorization update (October 2026) are already priced in. Watch for quarterly sales trends and any generic entry developments as patents approach expiry in the mid-2030s, but this drug alone will not drive MRK's share price.

Price Chart

Loading chart...

Executive Summary

DELSTRIGO is Merck's once-daily, fixed-dose combination tablet (doravirine/lamivudine/tenofovir disoproxil fumarate) for HIV-1 infection, originally FDA-approved in August 2018 and also authorized in the EU. It is a complete single-tablet regimen in the NNRTI class, competing primarily against Gilead's Biktarvy and other integrase-inhibitor-based regimens. Delstrigo generated approximately $75 million in Q1 2026 sales (up ~12% YoY), representing a small fraction of Merck's $65B+ annual revenue. The FDA approved a supplemental NDA in October 2026, and the European Commission updated its marketing authorization in the same month. With no upcoming binary catalysts and patent protection extending to the mid-2030s, Delstrigo is a steady but minor contributor to Merck's diversified portfolio.

How It Works

Delstrigo is a once-daily single tablet that combines three antiviral drugs: doravirine (a non-nucleoside reverse transcriptase inhibitor, or NNRTI), lamivudine (a nucleoside reverse transcriptase inhibitor, or NRTI), and tenofovir disoproxil fumarate (another NRTI). Together, these drugs block the HIV virus from replicating by interfering with the reverse transcriptase enzyme the virus needs to multiply. It is a complete regimen, meaning patients take one pill once a day with no other HIV medications needed.

Trial Status

Delstrigo was approved by the FDA on August 30, 2018, based on Phase 3 trials (DRIVE-AHEAD, DRIVE-FORWARD) in treatment-naive adults. A supplemental approval in 2022 expanded the label to include virologically suppressed patients switching therapy (DRIVE-SHIFT trial) and pediatric patients weighing at least 35 kg. The most recent FDA supplement (sNDA S-019) was approved on/about October 1, 2026. The drug is commercially available in the US and EU.

The Two-Sided Case

▲ Bull Case5
Delstrigo is a once-daily complete regimen offering convenience for HIV patients, with a growing sales trajectory (3-year CAGR of 26.4% from FY2022 to FY2025).
Q1 2026 sales of $75M grew 11.9% year-over-year, showing continued commercial momentum.
The FDA approved a supplemental NDA in October 2026 (NDA 210807/S-019), and the European Commission updated marketing authorization in October 2026, supporting ongoing label evolution.
As a Merck product, Delstrigo benefits from Merck's massive commercial infrastructure and global reach in infectious diseases.
Patent protection through the mid-2030s provides a long exclusivity runway with no near-term generic threat.
▼ Bear Case5
Delstrigo faces intense competition from Gilead's Biktarvy, the market-leading single-tablet HIV regimen, which has superior efficacy and tolerability profiles.
The HIV treatment market is shifting toward integrase strand transfer inhibitor (INSTI)-based regimens, while Delstrigo is NNRTI-based, putting it at a structural disadvantage.
At roughly $300M annual run rate, Delstrigo is a rounding error within Merck's $65B+ total revenue, so even strong growth has negligible impact on MRK's stock.
Patent protection extends to the mid-2030s, but a Paragraph IV challenge has been filed, creating generic overhang risk.
Tenofovir disoproxil fumarate (TDF) component is an older formulation associated with renal and bone safety concerns versus newer tenofovir alafenamide (TAF)-based regimens.

Upcoming Catalysts

  • No hard binary catalysts scheduled. Quarterly sales reports are the main ongoing event to track commercial trajectory.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Merck & Co., Inc. 8-K MRK ·Originating report

Sources · 11

Hover a chip for the title
1 en.wikipedia.org2 merck.com3 assyro.com4 opencapital.sh5 bioplayground.com6 drugs.com7 drugpatentwatch.com8 cliffbio.com9 drugs.com10 sec.gov11 accessdata.fda.gov